Sentence: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer ( TURANDOT ): primary endpoint results of a randomised , open-label , non-inferiority , phase 3 trial .
Drug combination annotation:
[{'class': 'POS', 'spans': ['bevacizumab', 'capecitabine'], 'is_context_needed': True}, {'class': 'COMB', 'spans': [0, 1], 'is_context_needed': True}]